The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) and the Pravastatin or Atorvastatin Evaluation and Infection Therapy Trial (PROVE-IT) showed that patients who met both targets of low-density lipoprotein cholesterol (LDL-C) <70 mg/dL and high-sensitivity C-reactive protein (hs-CRP) <2 mg/L had the best clinical outcomes.

Authors

• Person: Not available Organization: National Lipid Association
  EBM Tools for Practice: Best Biomarkers for Inflammation

Sources

• EBM Tools for Practice: Best Biomarkers for Inflammation www.lipid.org National Lipid Association via serper

Referenced by nodes (2)

• high-sensitivity C-reactive protein concept
• low-density lipoprotein cholesterol concept